MedAdvisor R&D / Revenue
The R&D to Revenue Ratio of MedAdvisor (MDR.AX) as of Nov 11, 2026 is 7.66 %. In the previous year, R&D to Revenue Ratio was 9.08 % — a change of -15.60% (lower).
Get this data via API
Financial Data API
R&D / Revenue
7.66 %
YoY
-15.60%
Last updated:
The MedAdvisor R&D / Revenue history
3 Years
10 Years
25 Years
Max
| YEAR | R&D / Revenue | YoY |
|---|---|---|
| 7.66 % | -15.60% | |
| 9.08 % | -23.98% | |
| 11.94 % | -47.21% | |
| 22.62 % | -19.76% | |
| 28.19 % | +133.45% | |
| 12.08 % | +100.40% | |
| 6.03 % | -54.04% | |
| 13.11 % | +22.61% | |
| 10.69 % | -89.31% | |
| 100.00 % | — |
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
MedAdvisor Stock analysis
Frequently Asked Questions about MedAdvisor stock
R&D to Revenue Ratio of MedAdvisor is 7.66 % in 2023.
R&D to Revenue Ratio of MedAdvisor changed from 9.08 % to 7.66 %, representing a -15.60% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of R&D to Revenue Ratio MedAdvisor since 2006 – with annual values, charts, and detailed analysis.
The R&D to Revenue ratio shows what percentage of revenue a company invests in research and development. Higher ratios indicate stronger focus on innovation.
A 'good' varies by industry and company stage. On Eulerpool, you can compare R&D to Revenue Ratio's MedAdvisor with sector peers and the industry average to assess whether it is attractive.
To evaluate R&D to Revenue Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for R&D to Revenue Ratio.
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Margins — MedAdvisor
All Key Metrics — MedAdvisor
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth